FierceBiotech  7 hrs ago  Comment 
Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.
Forbes  8 hrs ago  Comment 
Entresto. That's the brand name Novartis has chosen for LCZ696, its new heart failure drug that is expected to be a blockbuster. The name won't be final until official confirmation, which comes with FDA approval. But Novartis will...
newratings.com  May 21  Comment 
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors Novartis International AG / Novartis drug Afinitor® extended progression-free survival in Phase III trial...
Benzinga  May 20  Comment 
Novartis announced today positive results from two pivotal Phase III clinical trial programs for QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide) in patients with moderate-to-severe chronic obstructive pulmonary...
newratings.com  May 20  Comment 
Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 Novartis International AG / Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 . Processed and transmitted by NASDAQ OMX...
guardian.co.uk  May 17  Comment 
World Health Organisation rejects expensive licensed drug Lucentis to be added to list for all countries in favour of much cheaper Avastin, not yet available in UK All countries should make available a cheap, unlicensed drug to prevent blindness...
GenEng News  May 15  Comment 
Cortendo said today it will expand its rare-disease pipeline by acquiring one drug candidate and licensing another, in deals totaling up-to-$140 million-plus—as well as fund future development of the compounds by raising about $33.2 million...
newratings.com  May 15  Comment 
BASEL (dpa-AFX) - Microbix Biosystems Inc. (MBX.TO) announced the District Court in Texas has ruled in favour of Novartis, the defendant, in an infringement suit related to the 18 patent claims asserted by Microbix on its patent 7,270,990 in the...
FierceBiotech  May 14  Comment 
Biotech investor MPM Capital has put together a $400 million new fund with help from Big Pharma, scouting for innovative startups with an eye on build-to-buy deals.
FiercePharma  May 14  Comment 
When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki